HRA PHARMA
Acquired by
PERRIGO COMPANY
HRA PHARMA acquired by PERRIGO COMPANY
Target
HRA PHARMA
Acquirer
PERRIGO COMPANY
Context
The acquisition of HRA Pharma by Perrigo signifies the "crowning achievement" of the acquirer’s structural transformation into a pure-play consumer self-care leader. The strategic rationale for this transaction centers on a "portfolio-premium" maneuver, merging the target’s high-growth, margin-accretive branded assets with the acquirer’s massive expert direct go-to-market platform. This structural alignment provides the organization with the scientific talent and regulatory hardware necessary to dominate high-potential European markets and accelerate the "Rx-to-OTC" pipeline globally. This maneuver allows the group to execute a definitive structural expansion of its global footprint, particularly by adding significant scale in key underpenetrated European regions where the target maintains a dominant leadership position. By incorporating the target's seasoned leadership team and its expertise in specialized categories like emergency contraception and blister care, the organization is now positioned to leverage its recognized manufacturing depth to drive deeper penetration into adjacent self-care categories.
HRA PHARMA, which reported an EBITDA margin of LOGIN in 2022, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN premium to the 13.3x average currently observed in the Healthcare & Pharma sector.
Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.
-> Deep-dive in Healthcare & Pharma market trends
Target
HRA Pharma is a high-growth, innovative consumer healthcare organization that thrives on a philosophy of empowering individuals through accessible, value-added self-care solutions. The organization operates as a specialist in the development and marketing of market-leading brands across three core technical domains: women's health, blister care, and scar care. A primary pillar of its strategy is the "Rx-to-OTC" switch expertise, a sophisticated regulatory and commercial process that transitions prescription-only medications into the non-prescription retail landscape.
Ent. Value
LOGIN
Equity Value
LOGIN
Multiples Analysis
EV / Revenue
LOGIN
EV / EBITDA
LOGIN
EV / EBIT
LOGIN
Historical Financials (EUR)
Other operations with HRA PHARMA
| Date | Acquirer | Target | Country | Sector | Deal Context |
|---|---|---|---|---|---|
| 02/2016 | ASTORG / GOLDMAN SACHS | HRA PHARMA | FRANCE | Generics / Labs | Astorg and Goldman Sachs have completed the acquisition of HRA Pharma, signaling a major professionalization phase for the niche pharmaceutical laboratory. The strategic rationale for this transaction hinges on an "international-acceleration" maneuver, merging the target’s technical operational depth in hormonal health with the sponsors’ massive global network and institutional resources. This structural alignment provides the organization with the strategic hardware and capital necessary to target aggressive expansion into the United States and other high-potential global markets. The move specifically leverages the target's unique Rx-to-OTC switch prowess, a high-barrier technical capability that transforms clinical assets into scalable consumer brands. By incorporating the sponsors' strategic discipline, the group is now positioned to pivot from a European-centric leader to a global champion in the women’s health segment. |
mynth data is contributed by M&A / PE professionals and systematically cross-verified against private deal documents and official releases. All source materials are destroyed post-validation to guarantee data anonymity and compliance.